Evidence map›Paper›PMID 32395914›Full record

ArticleESC heart failure2020

Contemporary use of devices in chronic heart failure in the Netherlands.

Anne G Raafs, Gerard C M Linssen, Jasper J Brugts, Ayten Erol-Yilmaz, Jacobus Plomp, Jeroen P P Smits, Michiel J Nagelsmit, Remko M Oortman, Arno W Hoes, Hans-Peter Brunner-LaRocca

Open access · goldAbstract read
In one paragraph

Article in ESC heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Personalized Heart Failure Management: Bridging Technology and Care.Journal of the American Heart Association · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Anne G RaafsDepartment of Cardiology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Gerard C M LinssenDepartment of Cardiology, Hospital Group Twente, Almelo and Hengelo, The Netherlands.
Jasper J BrugtsDepartment of Cardiology, Erasmus Medical Centre, Thoraxcentre, Rotterdam, The Netherlands.
Ayten Erol-YilmazDepartment of Cardiology, Bernhoven Hospital, Uden, The Netherlands.
Jacobus PlompDepartment of Cardiology, Tergooi, Blaricum/Hilversum, The Netherlands.
Jeroen P P SmitsDepartment of Cardiology, Zuwe Hofpoort Hospital, Woerden, The Netherlands.
Michiel J NagelsmitDepartment of Cardiology, Scheper Hospital, Emmen, The Netherlands.
Remko M OortmanDepartment of Cardiology, Bravis Hospital, Bergen op Zoom, The Netherlands.
Arno W HoesJulius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht and Utrecht University, Utrecht, The Netherlands.
Hans-Peter Brunner-LaRoccaDepartment of Cardiology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Maastricht University Medical Centre · NLBravis Ziekenhuis · NLErasmus University Rotterdam · NLEuropean Organisation for Research and Treatment of Cancer · NLTergooi · NLTreant Zorggroep · NLUtrecht University · NLZiekenhuis Bernhoven · NLZiekenhuis Groep Twente · NL

Funding

Servier, the Netherlands
6 · The paper itself

Abstract

aimsDespite previous surveys regarding device implantation rates in heart failure (HF), insight into the real-world management with devices is scarce. Therefore, we investigated device implantation rates in HF with reduced left ventricular ejection fraction (LVEF) in 34 Dutch centres. METHODS AND

resultsA cross-sectional outpatient registry was conducted in 6666 patients with LVEF < 50% and with information about device implantation available [74 (66-81) years of age; 64% male]. Patients were classified into conventional pacemakers (PM, n = 562), implantable cardioverter defibrillators (ICD, n = 1165), and cardiac resynchronization therapy with defibrillator function (CRT-D, n = 885) or pacemaker function only (CRT-P, n = 248), or no device (n = 3806). Centres were divided into ICD-implanting and CRT-implanting and referral centres. Overall, 17.5% had an ICD, 13.3% CRT-D, 3.7% CRT-P, and 8.4% PM. Of those with LVEF ≤ 30%, 42.5% had ICD or CRT-D therapy. A large variation in implantation rates existed between centres: 3-51% for ICD therapy, 0.3-44% for CRT-D therapy, 0-11% for CRT-P therapy, and 0-25% PM therapy. Implantation centres showed higher implantation rates of ICD, CRT-D, and CRT-P compared with referral centres [36% vs. 25% for defibrillators (ICD or CRT-D) and 17% vs. 9% for CRT devices (CRT-D or CRT-P), respectively, P < 0.001], independently of other factors. A large number of clinical factors were predictive for device usage. Among other, LVEF < 40% and male sex were independent positive predictors for ICD/CRT-D use [odds ratio (OR) = 3.33, P < 0.001; OR = 1.87, P = 0.019, respectively]. Older age was independently associated with less ICD/CRT-D (OR = 0.96 per year, P < 0.001) and more CRT-P/PM use (OR = 1.03 per year, P = 0.006).

conclusionsIn this large Dutch HF registry, less than half of the patients with reduced LVEF received an ICD or CRT, even if LVEF was ≤30%, and a large variation between centres existed. Patients from implantation centres had more often ICD or CRT. More uniformity regarding guideline-based use of device therapy in clinical practice is needed.

Indexed as

Heart FailureVentricular Function, LeftAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedNetherlandsStroke VolumeCardiac resynchronization therapyElectrical device therapyHeart failureImplantable cardioverter defibrillatorReal-world heart failure management

Identifiers

PMID32395914
PMCPMC7373943
OpenAlexW3025885119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.